HealthcareServices

Type 2 Diabetes Market Forecast 2026: Where the Industry Is Headed

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the type 2 diabetes market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Type 2 Diabetes Market?

The type 2 diabetes market has experienced substantial expansion over recent years. This market is projected to expand from $51.47 billion in 2025 to $55.53 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.9%. The factors contributing to this historical growth include an increase in global obesity, more sedentary lifestyles, wider availability of oral antidiabetic medications, greater screening efforts for metabolic conditions, and enhanced access to fundamental diabetes care.

The type 2 diabetes market size is anticipated to experience substantial growth over the next few years. It is projected to expand to $78.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This projected growth is driven by increasing demand for therapies focused on weight management, the rising adoption of personalized diabetes treatment plans, the expansion of digital therapeutic platforms, a growing emphasis on preventive diabetes management, and increasing investments in next-generation antidiabetic drugs. Significant trends expected during this forecast period include the increasing uptake of GLP-1 receptor agonists, a rising focus on cardiometabolic risk management, the growing use of combination drug therapies, the expansion of lifestyle-integrated treatment approaches, and an enhanced emphasis on long-term glycemic control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

What Drivers Are Supporting Technological Adoption In The Type 2 Diabetes Market?

The growth of the type 2 diabetes market is projected to be propelled by an increase in rates of obesity and heart disease. Obesity is characterized as a medical condition where excessive body fat accumulates to an unhealthy degree, whereas heart disease encompasses various conditions affecting the heart and blood vessels. An abundance of body weight elevates the risk of insulin resistance, which in turn leads to high blood sugar levels and the progression of type 2 diabetes. Conversely, elevated blood sugar levels can impair the blood vessels and nerves that govern the heart and blood vessels, thereby contributing to heart disease. For example, in March 2024, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, disclosed that approximately one in eight people globally were contending with obesity. This statistic involved 2.5 billion adults (aged 18 years and older) classified as overweight, with 890 million of them living with obesity. Among the adult population, 43% were overweight, and 16% were deemed obese. Moreover, the population of overweight children under the age of 5 reached 37 million. Therefore, the escalating incidence of obesity and heart disease is a significant driver for the expansion of the type 2 diabetes market.

What Segment Types Are Examined In The Type 2 Diabetes Market?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

What Trends Are Driving The Growth Trajectory Of The Type 2 Diabetes Market?

Leading companies in the type 2 diabetes market are prioritizing the development of advanced solutions, such as extended-indication SGLT2/GLP-1 combination therapies, to achieve superior glycemic control, minimize comorbidities, and enhance patient adherence. These extended-indication SGLT2/GLP-1 combination therapies denote pharmaceutical protocols that integrate sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (or their fixed-dose versions) to concurrently address blood glucose regulation, obesity, and cardiovascular and renal outcomes in individuals with type 2 diabetes. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, obtained U.S. FDA approval for Farxiga (dapagliflozin) for the paediatric type 2 diabetes indication (age 10 years and older), signifying an expansion of its use beyond adult populations and a broader patient-base approach. This innovation provides once-daily oral dosing for younger patients, incorporates cardiometabolic and renal protection data, and facilitates market entry into paediatric and early-stage type 2 diabetes segments, thereby stimulating growth in the global type 2 diabetes market.

Who Are The Primary Competitors In The Global Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Which Regions Are Projected To Dominate The Type 2 Diabetes Market In The Coming Years?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Type 2 Diabetes Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Diabetes Care Devices Market 2026

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Type 1 Diabetes Market Report 2026

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795